These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35116896)

  • 1. Plasma cell-free DNA integrity: a potential biomarker to monitor the response of breast cancer to neoadjuvant chemotherapy.
    Wang W; Zhang W; Su L; Sang J; Wang S; Yao Y
    Transl Cancer Res; 2019 Aug; 8(4):1531-1539. PubMed ID: 35116896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer.
    Cirmena G; Ferrando L; Ravera F; Garuti A; Dameri M; Gallo M; Barbero V; Ferrando F; Del Mastro L; Garlaschi A; Friedman D; Fregatti P; Ballestrero A; Zoppoli G
    JCO Precis Oncol; 2022 Feb; 6():e2100198. PubMed ID: 35201850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma cell-free DNA integrity plus circulating tumor cells: a potential biomarker of no distant metastasis breast cancer.
    Wang W; Liang M; Ma G; Li L; Zhou W; Xia T; Xie H; Wang S
    Neoplasma; 2017; 64(4):611-618. PubMed ID: 28485169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
    Cheng J; Holland-Letz T; Wallwiener M; Surowy H; Cuk K; Schott S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Burwinkel B
    Breast Cancer Res Treat; 2018 May; 169(1):69-82. PubMed ID: 29340881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alter circulating cell-free DNA variables in plasma of ovarian cancer patients.
    Yu Z; Qin S; Wang H
    J Obstet Gynaecol Res; 2019 Nov; 45(11):2237-2242. PubMed ID: 31502389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating cell-free DNA variables as marker of ovarian cancer patients: A pilot study.
    Stamenkovic S; Cheng J; Surowy H; Burwinkel B; Gündert M
    Cancer Biomark; 2020; 28(2):159-167. PubMed ID: 32176629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis.
    Madhavan D; Wallwiener M; Bents K; Zucknick M; Nees J; Schott S; Cuk K; Riethdorf S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Surowy H; Burwinkel B
    Breast Cancer Res Treat; 2014 Jul; 146(1):163-74. PubMed ID: 24838941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Cell-Free DNA Integrity Is Associated with Poor Breast Cancer Survival.
    Lamminaho M; Kujala J; Peltonen H; Tengström M; Kosma VM; Mannermaa A
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-free circulating DNA integrity is an independent predictor of impending breast cancer recurrence.
    Cheng J; Cuk K; Heil J; Golatta M; Schott S; Sohn C; Schneeweiss A; Burwinkel B; Surowy H
    Oncotarget; 2017 Aug; 8(33):54537-54547. PubMed ID: 28903362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Role of Cell-free DNA Integrity in Thyroid Cancer Particularly for Bethesda IV Cytology.
    Higazi AM; El Hini SH; El-Sharkawy EA; Gayyed MF; Aziz NA; Matta RA
    Endocr Pract; 2021 Jul; 27(7):673-681. PubMed ID: 33601025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limited Utility of Circulating Cell-Free DNA Integrity as a Diagnostic Tool for Differentiating Between Malignant and Benign Thyroid Nodules With Indeterminate Cytology (Bethesda Category III).
    Thakur S; Tobey A; Daley B; Auh S; Walter M; Patel D; Nilubol N; Kebebew E; Patel A; Jensen K; Vasko V; Klubo-Gwiezdzinska J
    Front Oncol; 2019; 9():905. PubMed ID: 31620364
    [No Abstract]   [Full Text] [Related]  

  • 12. Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer.
    Skarping I; Förnvik D; Zackrisson S; Borgquist S; Rydén L
    Breast Cancer Res Treat; 2021 Aug; 189(1):131-144. PubMed ID: 34120224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma Cell-Free DNA as a Novel Biomarker for the Diagnosis and Monitoring of Atherosclerosis.
    Qian B; Li K; Lou X; Guo Y; Wang Y; Wu L; Zhang D
    Cells; 2022 Oct; 11(20):. PubMed ID: 36291116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma Cell-Free DNA Concentration and Fragmentomes Predict Neoadjuvant Chemotherapy Response in Cervical Cancer Patients.
    Peng T; Zhang H; Li L; Cao C; Xu M; Liu X; Lin S; Wu P; Chu T; Liu B; Xu Y; Zhang Y; Wang Y; Yu J; Ding W; Jin X; Wu P
    Adv Sci (Weinh); 2024 Nov; 11(43):e2309422. PubMed ID: 39319610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients.
    Nakai K; Mitomi H; Alkam Y; Arakawa A; Yao T; Tokuda E; Saito M; Kasumi F
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):923-30. PubMed ID: 22083523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet-to-Lymphocyte Ratio Is Associated With Favorable Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Study on 120 Patients.
    Lusho S; Durando X; Mouret-Reynier MA; Kossai M; Lacrampe N; Molnar I; Penault-Llorca F; Radosevic-Robin N; Abrial C
    Front Oncol; 2021; 11():678315. PubMed ID: 34367964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-Free Circulating DNA Integrity Based on Peripheral Blood as a Biomarker for Diagnosis of Cancer: A Systematic Review.
    Cheng J; Tang Q; Cao X; Burwinkel B
    Cancer Epidemiol Biomarkers Prev; 2017 Nov; 26(11):1595-1602. PubMed ID: 28830871
    [No Abstract]   [Full Text] [Related]  

  • 18. Tumor infiltrating neutrophil might play a major role in predicting the clinical outcome of breast cancer patients treated with neoadjuvant chemotherapy.
    Geng SK; Fu SM; Ma SH; Fu YP; Zhang HW
    BMC Cancer; 2021 Jan; 21(1):68. PubMed ID: 33446143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes of serum miR34a expression during neoadjuvant chemotherapy predict the treatment response and prognosis in stage II/III breast cancer.
    Liu B; Su F; Li Y; Qi X; Liu X; Liang W; You K; Zhang Y; Zhang J
    Biomed Pharmacother; 2017 Apr; 88():911-917. PubMed ID: 28178621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of vascular endothelial growth factor and proliferation marker MIB1 are influenced by neoadjuvant chemotherapy in locally advanced breast cancer.
    Singh M; Capocelli KE; Marks JL; Schleicher RB; Finlayson CA; Seligman PA
    Appl Immunohistochem Mol Morphol; 2005 Jun; 13(2):147-56. PubMed ID: 15894927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.